{
    "nct_id": "NCT04577833",
    "official_title": "An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Diagnosed with metastatic castration-resistant prostate cancer (mCRPC), who in the opinion of the investigator may benefit from treatment in this study\n* Able to continue gonadotropin-releasing hormone analogues (GnRHa) therapy during the study if not surgically castrate (that is, participants who have not undergone bilateral orchiectomy)\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to (<=) 1\n* Willing to provide a tumor sample (archival) for determination of homologous recombination repair (HRR) gene alteration status\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic brain metastases\n* Prior disease progression during treatment with abiraterone acetate (AA) alone or when combined with a poly adenosine diphosphate (ADP)-ribose polymerase inhibitor (PARPi). Prior discontinuation of treatment with AA or PARPi due to AA- or PARPi related toxicity.\n* History or current diagnosis of myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML)\n* Known allergies, hypersensitivity, or intolerance to niraparib or AA or the corresponding excipients of niraparib/AA\n* Any medical condition that would make prednisone/prednisolone use contraindicated",
    "miscellaneous_criteria": ""
}